1887

n Cardiovascular Journal of South Africa - The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic heart failure : drug trends in cardiology

USD

 

Abstract

Extracted from text ... 42 The interest in determining the role of angiotensin receptor blockers (ARBs) across the whole continuum of cardio - vascular disease from hyper tension to heart failure lead to the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme, a com po site of three trials designed to examine a wide range of patients with chronic heart failure (CHF). Three South African cardiologists and a physician who participated in the CHARM programme met recently to review their experiences following the presentation of the results at the September 2003 European Society of Cardiology Meeting. The meeting was ..

Loading

Article metrics loading...

/content/cardio/15/1/EJC23874
2004-01-01
2016-12-06
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error